21 completed, 1 unknown. 22 Phase 3, 6 Phase 2.
By phase and status
Follow glecaprevir: new trials by email Literature Review of glecaprevir trials Research Report on glecaprevir
Trials (filtered) newest first · largest first
All 22 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD Phase 2 / Phase 3 Completed 10 2023-04-01 2024-08-29
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) Glecaprevir/Pibrentasvir (GLE/PIB) - Hepatitis C Virus (HCV) Phase 3 Completed 286 2021-08-24 2025-04-06
Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C Phase 2 / Phase 3 Completed 54 2019-03-22 2023-09-13
Transplantation Using Hepatitis C Positive Donors, A Safety Trial Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion - Lung Transplant Infection, Heart Transplant Infection Phase 3 Unknown 40 2018-08-06 2019-07-12
A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) Phase 3 Completed 100 2018-06-06 2020-03-17
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients glecaprevir (300mg)/pibrentasvir (120mg) - Hepatitis C, Chronic Phase 3 Completed 380 2017-08-21 2019-12-11
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) Phase 3 Completed 343 2017-04-28 2020-07-13
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet - Hepatitis C, HCV Phase 3 Completed 177 2017-04-20 2020-02-26
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation - Hepatitis C Virus (HCV) Phase 2 / Phase 3 Completed 129 2017-03-20 2023-05-09
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) ABT-493 coformulated with ABT-530 - Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection Phase 3 Completed 153 2016-05-17 2021-07-13
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) glecaprevir/pibrentasvir - Chronic Hepatitis C, HCV Phase 3 Completed 100 2016-04-22 2021-07-13
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection ABT-493/ABT-530, sofosbuvir (SOF), ribavirin (RBV) - Chronic Hepatitis C Virus, Hepatitis C Virus Phase 3 Completed 136 2016-04-08 2021-07-16
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection ABT-493/ABT-530, OBV/PTV/r - Chronic Hepatitis C Virus, Hepatitis C Virus Phase 3 Completed 295 2016-02-22 2021-07-16
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis ABT-493/ABT-530 - Hepatitis C Virus Infection, Chronic Hepatitis C Phase 3 Completed 146 2015-12-07 2021-07-13
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection ABT-493/ABT-530, Sofosbuvir, Daclatasvir - Chronic Hepatitis C, Hepatitis C Virus Phase 3 Completed 506 2015-12-01 2021-07-30
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection ABT-493/ABT-530 - Chronic Hepatitis C Virus (HCV) Infection Phase 3 Completed 104 2015-12-01 2017-10-16
The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) ABT-493/ABT-530 - Hepatitis C Virus Phase 3 Completed 121 2015-11-01 2021-07-13
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection ABT-493/ABT-530, Placebo for ABT-493/ABT-530 - Chronic Hepatitis C Virus (HCV) Infection Phase 3 Completed 304 2015-11-01 2021-07-16
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection ABT-493/ABT-530 - Chronic Hepatitis C, Hepatitis C Virus Phase 3 Completed 703 2015-10-01 2021-07-13
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 ABT-493, ABT-530 - Hepatitis C Phase 2 / Phase 3 Completed 384 2015-06-22 2020-09-21
Showing 20 of 22. Sign in to see all of them.
Conditions studied Hepatitis C (21) · Hepatitis C, Chronic (17) · Fibrosis (3) · Infections (3) · Acquired Immunodeficiency Syndrome (1) · Renal Insufficiency (1) · Stress Disorders, Post-Traumatic (1)
Sponsors AbbVie (17) · Jordan Feld (1) · Kirby Institute (1) · Ohio State University (1) · University of Florida (1) · White River Junction Veterans Affairs Medical Center (1)
Countries United States (8) · Canada (6) · Germany (4) · United Kingdom (4) · Australia (3) · France (3) · Puerto Rico (3) · Spain (3) · Belgium (2) · Italy (2) · New Zealand (2) · Russia (2) · Austria (1) · Brazil (1) · Bulgaria (1)
Top investigators Bradley V Watts, MD, MPH (1) · David R Nelson, MD (1) · Gregory Dore (1) · Jordan Feld, MD, MPH (1) · Reem Daloul, MD (1) · Susan Rhee, MD (1)
Results publications PMID 30977945 , PMID 30012435 , PMID 30923816 , PMID 31568620 , PMID 30529905 , PMID 30868245 , PMID 29180522 , PMID 35174470 , PMID 27456384 , PMID 28128852 , PMID 28865152 , PMID 28941361 , PMID 28951228 , PMID 29020583 , PMID 31254392 , PMID 31401140 , PMID 31655134 , PMID 31682879 , PMID 32389183 , PMID 32949786 , PMID 33811356 , PMID 34023351 , PMID 35220658 , PMID 41297677 , PMID 42189498 , PMID 42340583
NIH funding 2015 (10) , 2016 (2) , 2014 (1)